ValiRx plc (VAL) AI Stock Analysis

• Market Cap: £2.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 418.49%
• EPS Growth: 27.86%
• Country: UK
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 742,801,100
• 10 Day Avg. Volume: 510,641
• 30 Day Avg. Volume: 1,099,814
• PEG Ratio: 0.02
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 20.52
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: 0.37p ▼(-8.00% Downside)

ValiRx plc's overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.

Positive Factors

Strong equity position

A high equity ratio provides a durable capital buffer to support long development cycles and absorb setbacks. That equity strength reduces near-term insolvency risk, making the company a more stable partner for collaborators and better positioned to pursue clinical milestones before raising costly capital.

Low financial leverage

Minimal debt lowers fixed financial obligations and interest burden, preserving cash flexibility critical for R&D-intensive biotech. This structural conservatism reduces default risk during trial delays and gives management optionality to choose strategic funding via partnerships or targeted financings.

Diversified revenue model potential

Multiple non-dilutive and partnership-based revenue avenues create durable funding options as programs progress. Licensing and milestone structures can monetize assets without full commercialization risk, lowering dependency on equity markets and aligning incentives with larger pharma partners over time.

Negative Factors

Persistent unprofitability

Sustained net losses and negative margins undermine internal capital generation, forcing repeated external funding. Over the medium term this can dilute shareholders, constrain strategic freedom, and pressure management to prioritize short-term cash raises over optimal long-term R&D decisions.

Negative free cash flow and funding reliance

Negative free cash flow and dependence on financing create structural funding risk. Access to capital can be episodic and costly, which may delay trials or force unfavorable deals. Over months this raises execution risk for clinical timelines and diminishes runway if milestones slip.

Negative gross and operating margins

Negative gross and operating margins indicate the business cannot cover direct and overhead costs from current revenues. With a very low revenue base, scaling is inefficient and fixed costs weigh heavily, making it harder to reach sustainable margins without successful asset commercialization or cost restructuring.

ValiRx plc Business Overview & Revenue Model

Company Description

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

How the Company Makes Money

ValiRx generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model includes potential licensing agreements, partnerships with larger pharmaceutical companies, and grants for research and development. Key revenue streams may arise from milestone payments as products progress through clinical trials and achieve regulatory approvals, as well as royalties from sales of successfully commercialized drugs. Additionally, ValiRx may benefit from collaborations with academic institutions and other biotech firms that can provide funding and resources for its research initiatives.

ValiRx plc Financial Statement Overview

Summary

ValiRx plc is facing substantial financial challenges typical of a biotech firm in its growth phase, with ongoing net losses and reliance on external financing. While equity is strong, profitability and cash flow constraints pose significant risks. The company needs to improve operational efficiency and revenue generation to enhance financial stability and investor confidence.

Income Statement

ValiRx plc exhibits a challenging income statement with negative profitability margins. The gross profit margin is negative due to the cost of revenue exceeding total revenue, and the net profit margin is significantly negative, indicating substantial losses relative to revenue. Revenue growth is present, but the base is very low, which makes the growth percentage less impactful. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high operating expenses.

Balance Sheet

The balance sheet shows a relatively solid equity position compared to liabilities, with a high equity ratio. However, the debt-to-equity ratio is low, indicating minimal leverage, which can be a double-edged sword in biotech if additional funding is needed. Return on equity is negative, driven by continuous net losses, signaling the need for improved profitability to enhance shareholder value.

Cash Flow

Cash flow statements reveal negative free cash flow, though there is a slight improvement in operating cash flow. The company relies heavily on financing activities for cash, which may not be sustainable long-term. The operating cash flow to net income ratio is negative, suggesting cash flow challenges in converting sales into cash. Free cash flow growth rates are negative, reflecting ongoing capital expenditure needs without sufficient revenue support.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.77K	9.60K	0.00	0.00	0.00
Gross Profit	-217.22K	-246.04K	-224.27K	-228.79K	-229.50K
EBITDA	-1.86M	-2.04M	-2.37M	-1.45M	-1.31M
Net Income	-1.92M	-2.04M	-2.41M	-1.55M	-1.47M
Balance Sheet
Total Assets	4.26M	3.13M	3.98M	3.52M	4.94M
Cash, Cash Equivalents and Short-Term Investments	1.56M	174.68K	1.14M	593.67K	1.85M
Total Debt	11.86K	22.07K	37.71K	58.72K	71.06K
Total Liabilities	346.41K	226.51K	149.65K	109.56K	182.40K
Stockholders Equity	4.32M	3.22M	4.05M	3.60M	4.91M
Cash Flow
Free Cash Flow	-1.62M	-2.08M	-1.71M	-1.26M	-2.00M
Operating Cash Flow	-1.58M	-1.77M	-1.71M	-1.26M	-1.91M
Investing Cash Flow	-38.16K	-306.18K	0.00	0.00	-91.29K
Financing Cash Flow	3.00M	1.12M	2.26M	7.34K	3.85M

ValiRx plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.35, and below the 200-day MA of 0.49, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.02 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.

ValiRx plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCLP	48 Neutral	£137.51M	-25.00	―	―	―	-94.12%
SAR	47 Neutral	£24.16M	-5.19	-202.14%	―	―	23.76%
HEMO	47 Neutral	£44.46M	-3.32	-609.30%	―	―	―
IMM	46 Neutral	£31.97M	-7.15	-259.88%	―	―	―
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
VAL	41 Neutral	£2.60M	-0.24	―	―	418.49%	27.86%

ValiRx plc Corporate Events

ValiRx Issues 80,000 New Shares Following Warrant Exercise

ValiRx plc has received notification for the exercise of warrants over 80,000 ordinary shares at an exercise price of 0.5 pence per share, raising gross proceeds of £400 for the company. The new shares will be admitted to trading on AIM around 23 January 2026, rank equally with existing ordinary shares, and will increase ValiRx’s issued share capital to 742,801,072 shares, a marginal capital change that slightly dilutes existing holdings while updating the share count used for regulatory disclosure thresholds.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.38 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx Strikes RNA Helicase Deal with McGill and IRICoR Under Asset-Focused Funding Model

ValiRx has signed a nine‑month evaluation and material transfer agreement with McGill University and Canadian non-profit IRICoR to assess a second-generation, orally available RNA helicase inhibitor, with its subsidiary Inaphaea Biolabs responsible for establishing target engagement and potency and owning the evaluation results. IRICoR will create a Canadian subsidiary, NewCo, to commercialise the evaluation results and background IP, with ValiRx having an option to license its results into NewCo for equity and potentially provide up to £2 million in staged seed funding alongside other investors, or alternatively receive a cash return of 1.5 times its evaluation investment if it elects not to proceed and the institutions later commercialise the technology; the structure is intended to attract external capital, advance a relatively late-stage oncology asset, and dilute risk at the asset level rather than at ValiRx plc, providing multiple routes to value creation for the company and its partners.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.40 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx Strikes RNA Helicase Inhibitor Deal with McGill and IRICoR to Drive Asset-Level Growth

ValiRx has entered into a nine‑month Evaluation and Material Transfer Agreement with McGill University and IRICoR to assess a second‑generation, orally available RNA helicase inhibitor, with its subsidiary Inaphaea Biolabs responsible for establishing target engagement and potency and owning the resulting evaluation data. Under the deal, IRICoR will create a new Canadian subsidiary, NewCo, to commercialise the evaluation results and background IP, with ValiRx holding an option to license the results into NewCo for a 15% equity stake and potentially provide up to £2m in seed funding, or alternatively receive a 1.5x return on its evaluation investment if it opts out, a structure that management says supports asset‑level dilution, attracts external funding and opens multiple strategic pathways to value creation in both human and veterinary health markets.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.40 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx Advances with New Equity and Warrant Issuance Post-General Meeting

ValiRx plc announced the successful passing of all resolutions at its recent General Meeting, paving the way for the issuance of new equity and warrants as part of its fundraising efforts. The company plans to admit 256,067,800 new shares to trading on AIM, with the issuance of 368,372,400 fundraising warrants and 16,036,120 broker warrants, which are exercisable until the third anniversary of the admission. This strategic move is expected to bolster ValiRx’s financial position, enabling further investment in its pipeline of cancer therapeutics and women’s health products, potentially enhancing its market position and delivering value to stakeholders.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx PLC Announces Fundraising to Boost Cancer and Women’s Health Research

ValiRx PLC has announced the posting of a circular and notice for a General Meeting to discuss a fundraising initiative aimed at raising approximately £902,000. The funds will support research and development efforts, including the preclinical development of Cytolytix and VAL201 2.0, as well as operational costs. This fundraising effort is part of ValiRx’s strategy to enhance the translation of novel research into clinical applications, focusing on oncology and women’s health. The issuance of new shares and warrants will significantly increase the company’s share capital, impacting its market positioning and providing resources for future growth.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx PLC Raises £902,000 Through Successful Fundraising

ValiRx PLC has successfully raised approximately £902,000 through its WRAP Retail Offer and other fundraising activities, issuing new ordinary shares at a price of 0.25 pence per share. This capital injection is expected to support the company’s ongoing operations and strategic initiatives, potentially strengthening its position in the life sciences industry and providing value to its stakeholders.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx Plc Raises £902,000 Through Successful WRAP Retail Offer

ValiRx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £152,000 through the issuance of new ordinary shares. Combined with previous fundraising efforts, the company has secured a total of £902,000. The new shares are expected to commence trading on AIM by 21 November 2025, subject to the approval of Fundraising Resolutions at the General Meeting. This fundraising effort is anticipated to bolster ValiRx’s financial position and support its strategic initiatives in the life sciences sector.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx Plc Launches £300,000 Retail Offer to Boost Cancer Therapeutics Development

ValiRx Plc has announced a retail offer via the Winterflood Retail Access Platform to raise up to £300,000 through the issuance of new ordinary shares and warrants. This initiative is part of a broader fundraising effort, where the company has conditionally raised £750,000 through a placing and subscription of new shares. The funds raised will support the company’s ongoing projects and operations. The offer is open to eligible retail investors in the UK and is expected to close on 3 November 2025, with the results announced shortly thereafter. This move aims to strengthen ValiRx’s financial position and expand its retail shareholder base.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

ValiRx PLC Launches £1.05 Million Fundraising to Boost Cancer and Women’s Health Initiatives

ValiRx PLC has announced a fundraising initiative to raise up to £1,050,000 through a combination of firm and conditional placings, a WRAP Retail Offer, and direct subscriptions by company directors. The initiative, which includes the issuance of new shares and fundraising warrants, aims to support the company’s operations in a challenging funding environment. The funds will be used to expand ValiRx’s evaluation pipeline and progress existing projects, enhancing its strategic position in the oncology and women’s health sectors.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.